查看文章

For patients with non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacille Calmette-Guerin (BCG), multi-agent intravesical trials have been limited. The goal of this study was to investigate the safety of intravesical chemotherapy consisting of sequential cabazitaxel, gemcitabine, and cisplatin (CGC) in the salvage setting. Funding support for the trial was provided by Sanofi Genzyme.

This was a dose-escalation, drug-escalation trial enrolling patients with BCG refractory or recurrent high-risk NMIBC who refused or were ineligible for radical cystectomy. All patients underwent a pre-treatment transurethral resection of bladder tumor (TURBT) and a 6-week regimen of intravesical chemotherapy, with each drug instilled weekly except for cisplatin, which was given every other week. Complete response was defined as no evidence of cancer on post-induction …